BIOMARKERS FOR CHRONIC LUNG DISEASES

Objectives

  • Review current status of biomarkers for three chronic lung diseases—asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis
  • Address current opportunities to evaluate genetic and physiologic (e.g., biochemical, imaging, and quality of life) biomarkers for chronic lung diseases
  • Identify potential genetic markers, markers of function, markers of therapeutic benefit, and promising new technological advances that offer improved capacity to precisely and accurately assess response to therapies
  • Determine research needs for the development, evaluation, and validation of biomarkers for these diseases
  • Identify new research questions and scientific approaches to evaluate promising biomarkers and advance preclinical research to clinical research
  • Identify potential data registries or databases for retrospective analyses or meta-analyses of potential biomarkers, intermediate endpoints, and surrogate endpoints

Agenda

Moderator: Sonia Buist, M.D., University of Oregon Health Sciences Center

Introduction
James Kiley, Ph.D., National Heart, Lung, and Blood Institute
Marshall Plaut, M.D., National Institute of Allergy and Infectious Diseases

Introductory Presentation
Biomarkers of Airway Inflammation in Asthma
William W. Busse, M.D., University of Wisconsin, Medical School, Madison

Session I. Asthma

Biomarkers in Asthma
Francis M. Cuss, M.D., Schering-Plough Research Institute

Biomarkers for Chronic Lung Diseases
Robert P. Schleimer, Ph.D., Johns Hopkins University

Discussants:  Jack Elias, M.D., Yale University School of Medicine
John Jenkins, M.D., Center for Drug Evaluation Research, U.S. Food and Drug Administration

Session II. Chronic Obstructive Pulmonary Disease

Assessing Biological Response In Vivo
Stephen I. Rennard, M.D., University of Nebraska Medical Center

Chronic Obstructive Pulmonary Disease, Functional Markers, Computerized Tomography, and Quality of Life
Robert A. Wise, M.D., Johns Hopkins University School of Medicine

Potential Genetic Biomarkers for COPD
Eugene R. Bleecker, M.D., University of Maryland

Discussants:  Theodore Reiss, M.D., Merck Research Laboratories
John Jenkins, M.D., Center for Drug Evaluation Research, U.S. Food and Drug Administration

Session III. Pulmonary Fibrosis

Biomarkers in Fibrogenic Lung Disease
Ronald H. Goldstein, M.D., Boston University Medical Center

Open Discussion: Panelists and Participants

Future Directions of Biomarkers for Chronic Lung Disease
Francis M. Cuss, M.D., Schering-Plough Research Institute

Discussant:  John Jenkins, M.D., Center for Drug Evaluation Research, U.S. Food and Drug Administration

Summation
James Kiley, Ph.D.
Marshall Plaut, M.D.
Sonia Buist, M.D.

Overview  Agenda  Registration  Conference Abstracts
  Hotel & Travel  Selected References 
Remote Video Conference Participation  Contact  NIH Home Page